Background/Objectives: The EGFR T790M gatekeeper mutation drives resistance in non-small cell lung cancer by sterically hindering inhibitors and restoring ATP affinity. As emerging C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur atom as a primary stabilizing anchor rather than a liability. Methods: A reinforcement learning-based generative AI framework (DrugEx) sampled 100,000 molecules, prioritized through QSAR-based classification (mean ROC-AUC: 0.91 ± 0.01) and physicochemical filtering. Four lead candidates underwent 200 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability and energetic convergence were quantified via Free Energy Landscape (FEL) analysis, post-simulation Ramachandran validation, and ensemble-averaged Molecular Mechanics Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Results: Candidate 106 demonstrated high mutation tolerance by redistributing interactions toward the Met790 sulfur atom, contrasting with reference scaffolds 14 and 88 which suffered significant affinity loss. MD analysis revealed that potency is fundamentally dictated by successful recruitment of the thioether environment, locking the complex within a narrow, well-defined thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol by docking) corroborated by a robust MM-GBSA ΔGbind of −50.51 kcal/mol, primarily driven by persistent π-sulfur contacts (85% occupancy). Ramachandran analysis confirmed over 90% favored region occupancy, ensuring interactions occur without non-physical protein strain. Conclusions: Successful T790M/C797S resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This mutation-aware blueprint provides a non-covalent strategy that avoids the metabolic and resistance-prone liabilities of covalent warheads.
Background/Objectives: The EGFR T790M mutation drives lung cancer resistance by sterically hindering inhibitors and restoring ATP affinity. As C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur as a primary stabilizing anchor rather than a liability. Methods: A generative AI framework (DrugEx) sampled 100,000 molecules, prioritized via QSAR classification (ROC-AUC: 0.91 ± 0.01) and Applicability Domain (AD) mapping. The workflow was de-risked through retrospective benchmarking against the DUD-E database (35,590 molecules), achieving a 1% Enrichment Factor of 5.19. Lead candidates underwent 100 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability was quantified via Free Energy Landscape (FEL) analysis and ensemble-averaged MM-GBSA binding free energy calculations. Results: Candidate 106 demonstrated exceptional mutation tolerance by redistributing interactions toward the Met790 sulfur atom. MD analysis confirmed potency is dictated by successful recruitment of the thioether environment, locking the complex within a narrow thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol) corroborated by an equipotent MM-GBSA ΔGbind of −50.51 kcal/mol in the mutant system, driven by persistent π-sulfur contacts (85% occupancy). Conclusions: These results indicates that potential T790M resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This modeled mutation-aware framework provides a candidate non-covalent strategy to be validated in future wet-lab campaigns.
The global escalation of antimicrobial resistance (AMR) poses significant threat to modern medicine. With ESKAPE pathogens particularly the carbapenem-resistant Acinetobacter baumannii emerging as priority targets for novel antimicrobial intervention. The peptidyl-tRNA hydrolase (Pth), an essential enzyme responsible for recycling stalled peptidyl-tRNA molecules during abortive protein translation. It is a highly conserved yet substantially underexplored antimicrobial target. The bacterial form (Pth1) is structurally and sequentially distinct from its human ortholog (Pth2), conferring inherent selectivity advantages. In the present study, an AI-assisted de novo design strategy employing the REINVENT 4 generative modelling platform was integrated with structure-based virtual screening, molecular dynamics (MD) simulation, MM-GBSA binding free energy calculations, and ADME profiling to identify and prioritize small-molecule binders. From a virtual library of approximately 0.18 million generative AI-derived molecules were subjected to validated molecular docking. Total six top-ranked candidates (S1–S6) were shortlisted on the basis of binding affinity, interaction profiles, and synthetic accessibility. Among these, two candidates S1, a glutamic acid derivative (MW 267.07 Da), and S5, a phenylalanine derivative (MW 241.11 Da) were synthesized and fully characterized by FT-IR, 1H NMR, and Mass spectrometry. The compound S1 exhibitedgrowth of inhibition by 52% at a concentration of 100 µg/mL in-vitro microbial study againstStaphylococcus aureus. The stability of protein-ligand complex was authenticated by Molecular dynamics (MD) simulations over 100 ns trajectories, with RMSD values predominantly below 2.5 Å. Network pharmacology and predicted interactome mapping were performed to portray the poly-pharmacological profiles of the compound S1 and S5. Such study revealedthat functional clusters are associated with epigenetic regulation, signaling cascades, DNA damage response and proteostasis. The selectivity of the scaffolds in direction with bacterial Pth over human PTPN6 was identified by Structural alignment and BLAST analysis. Such study suggests that the compound are safe and broad-spectrum antimicrobial leads.